APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Live Attenuated Vaccines Industry Growth and Trends Forecast to 2032

20 December 202594 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccines Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccines Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Vaccines include Astellas Pharma, CSL, Serum Institute Of India, GlaxoSmithKline, Pfizer, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Live Attenuated Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Live Attenuated Vaccines market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Live Attenuated Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Live Attenuated Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Live Attenuated Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Live Attenuated Vaccines Market by Company

Astellas Pharma

CSL

Serum Institute Of India

GlaxoSmithKline

Pfizer

Merck

Johnson & Johnson

Sanofi

Live Attenuated Vaccines Segment by Type

Bacterial

Viral

Live Attenuated Vaccines Segment by Application

Research Institutes

Hospitals

Clinics

Others

Live Attenuated Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Bacterial Table 2. Major Company of Viral Table 3. Global Live Attenuated Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 5. Global Live Attenuated Vaccines Sales Market Share in Volume by Type (2021-2026) Table 6. Global Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 7. Global Live Attenuated Vaccines Sales Market Share in Value by Type (2021-2026) Table 8. Global Live Attenuated Vaccines Price by Type (2021-2026) & (US$/Unit) Table 9. Global Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 10. Global Live Attenuated Vaccines Sales Market Share in Volume by Type (2027-2032) Table 11. Global Live Attenuated Vaccines Sales by Type (2027-2032) & (US$ Million) Table 12. Global Live Attenuated Vaccines Sales Market Share in Value by Type (2027-2032) Table 13. Global Live Attenuated Vaccines Price by Type (2027-2032) & (US$/Unit) Table 14. North America Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 15. North America Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 17. Europe Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 21. Latin America Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Live Attenuated Vaccines Sales by Type (2021-2026) & (US$ Million) Table 24. Live Attenuated Vaccines Industry Trends Table 25. Live Attenuated Vaccines Industry Drivers Table 26. Live Attenuated Vaccines Industry Opportunities and Challenges Table 27. Live Attenuated Vaccines Industry Restraints Table 28. Global Live Attenuated Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Live Attenuated Vaccines Revenue Market Share by Company (2021-2026) Table 30. Global Live Attenuated Vaccines Sales by Company (2021-2026) & (K Units) Table 31. Global Live Attenuated Vaccines Sales Share by Company (2021-2026) Table 32. Global Live Attenuated Vaccines Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Live Attenuated Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Live Attenuated Vaccines Major Company Production Sites and Headquarters Table 35. Global Live Attenuated Vaccines Company, Product Type & Application Table 36. Global Live Attenuated Vaccines Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Live Attenuated Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Live Attenuated Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Live Attenuated Vaccines Sales by Region (2021-2026) & (K Units) Table 41. Global Live Attenuated Vaccines Sales Market Share in Volume by Region (2021-2026) Table 42. Global Live Attenuated Vaccines Sales by Region (2021-2026) & (US$ Million) Table 43. Global Live Attenuated Vaccines Sales Market Share in Value by Region (2021-2026) Table 44. Global Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Live Attenuated Vaccines Sales by Region (2027-2032) & (K Units) Table 46. Global Live Attenuated Vaccines Sales Market Share in Volume by Region (2027-2032) Table 47. Global Live Attenuated Vaccines Sales by Region (2027-2032) & (US$ Million) Table 48. Global Live Attenuated Vaccines Sales Market Share in Value by Region (2027-2032) Table 49. Global Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Live Attenuated Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 52. Global Live Attenuated Vaccines Sales Market Share in Volume by Application (2021-2026) Table 53. Global Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 54. Global Live Attenuated Vaccines Sales Market Share in Value by Application (2021-2026) Table 55. Global Live Attenuated Vaccines Price by Application (2021-2026) & (US$/Unit) Table 56. Global Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 57. Global Live Attenuated Vaccines Sales Market Share in Volume by Application (2027-2032) Table 58. Global Live Attenuated Vaccines Sales by Application (2027-2032) & (US$ Million) Table 59. Global Live Attenuated Vaccines Sales Market Share in Value by Application (2027-2032) Table 60. Global Live Attenuated Vaccines Price by Application (2027-2032) & (US$/Unit) Table 61. North America Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 62. North America Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 64. Europe Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 68. Latin America Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Live Attenuated Vaccines Sales by Application (2021-2026) & (US$ Million) Table 71. Astellas Pharma Company Information Table 72. Astellas Pharma Business Overview Table 73. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Astellas Pharma Live Attenuated Vaccines Product Portfolio Table 75. Astellas Pharma Recent Development Table 76. CSL Company Information Table 77. CSL Business Overview Table 78. CSL Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CSL Live Attenuated Vaccines Product Portfolio Table 80. CSL Recent Development Table 81. Serum Institute Of India Company Information Table 82. Serum Institute Of India Business Overview Table 83. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Serum Institute Of India Live Attenuated Vaccines Product Portfolio Table 85. Serum Institute Of India Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Live Attenuated Vaccines Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Pfizer Live Attenuated Vaccines Product Portfolio Table 95. Pfizer Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck Live Attenuated Vaccines Product Portfolio Table 100. Merck Recent Development Table 101. Johnson & Johnson Company Information Table 102. Johnson & Johnson Business Overview Table 103. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Johnson & Johnson Live Attenuated Vaccines Product Portfolio Table 105. Johnson & Johnson Recent Development Table 106. Sanofi Company Information Table 107. Sanofi Business Overview Table 108. Sanofi Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Sanofi Live Attenuated Vaccines Product Portfolio Table 110. Sanofi Recent Development Table 111. North America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. North America Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 113. North America Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 114. North America Live Attenuated Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 115. North America Live Attenuated Vaccines Sales Market Share Forecast by Country (2027-2032) Table 116. North America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Live Attenuated Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Live Attenuated Vaccines Market Share by Country (2021-2026) Table 119. North America Live Attenuated Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Live Attenuated Vaccines Market Share Forecast by Country (2027-2032) Table 121. Europe Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Europe Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 123. Europe Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 124. Europe Live Attenuated Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 125. Europe Live Attenuated Vaccines Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Live Attenuated Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Live Attenuated Vaccines Market Share by Country (2021-2026) Table 129. Europe Live Attenuated Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Live Attenuated Vaccines Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 133. Asia-Pacific Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Live Attenuated Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 135. Asia-Pacific Live Attenuated Vaccines Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Live Attenuated Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Live Attenuated Vaccines Market Share by Country (2021-2026) Table 139. Asia-Pacific Live Attenuated Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Live Attenuated Vaccines Market Share Forecast by Country (2027-2032) Table 141. Latin America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Latin America Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 143. Latin America Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 144. Latin America Live Attenuated Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 145. Latin America Live Attenuated Vaccines Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Live Attenuated Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Live Attenuated Vaccines Market Share by Country (2021-2026) Table 149. Latin America Live Attenuated Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Live Attenuated Vaccines Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 153. Middle East and Africa Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Live Attenuated Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Live Attenuated Vaccines Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Live Attenuated Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Live Attenuated Vaccines Market Share by Country (2021-2026) Table 159. Middle East and Africa Live Attenuated Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Live Attenuated Vaccines Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Live Attenuated Vaccines Distributors List Table 164. Live Attenuated Vaccines Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Live Attenuated Vaccines Image Figure 2. Global Live Attenuated Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Vaccines Sales (2021-2032) & (K Units) Figure 5. Bacterial Image Figure 6. Global Bacterial Sales YoY Growth (2021-2032) & (K Units) Figure 7. Viral Image Figure 8. Global Viral Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Live Attenuated Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Live Attenuated Vaccines Market Share by Type 2025 VS 2032 Figure 11. North America Live Attenuated Vaccines Sales Market Share in Volume by Type in 2025 Figure 12. North America Live Attenuated Vaccines Sales Market Share in Value by Type in 2025 Figure 13. Europe Live Attenuated Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. Europe Live Attenuated Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Live Attenuated Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Live Attenuated Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Latin America Live Attenuated Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Live Attenuated Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Live Attenuated Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Live Attenuated Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Live Attenuated Vaccines Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Research Institutes Image Figure 24. Global Research Institutes Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Live Attenuated Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Live Attenuated Vaccines Market Share by Application 2025 VS 2032 Figure 33. North America Live Attenuated Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. North America Live Attenuated Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Europe Live Attenuated Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Europe Live Attenuated Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Live Attenuated Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Live Attenuated Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Latin America Live Attenuated Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Live Attenuated Vaccines Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Live Attenuated Vaccines Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Live Attenuated Vaccines Sales Market Share in Value by Application in 2025 Figure 43. North America Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Live Attenuated Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Live Attenuated Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Live Attenuated Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Live Attenuated Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Live Attenuated Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Live Attenuated Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Live Attenuated Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Live Attenuated Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Live Attenuated Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Live Attenuated Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Live Attenuated Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Live Attenuated Vaccines Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Live Attenuated Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial
  • Viral
Applications
  • Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Astellas Pharma
  • CSL
  • Serum Institute Of India
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Live Attenuated Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Live Attenuated Vaccines Market by Type
  6. 1.3.1 Bacterial
  7. 1.3.2 Viral
  8. 1.4 Global Live Attenuated Vaccines Market Size by Type
  9. 1.4.1 Global Live Attenuated Vaccines Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Live Attenuated Vaccines Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Live Attenuated Vaccines Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Live Attenuated Vaccines Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Live Attenuated Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Live Attenuated Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Live Attenuated Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Live Attenuated Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Live Attenuated Vaccines Industry Trends
  2. 2.2 Live Attenuated Vaccines Industry Drivers
  3. 2.3 Live Attenuated Vaccines Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Live Attenuated Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Live Attenuated Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Live Attenuated Vaccines Price (2021-2026)
  4. 3.4 Global Live Attenuated Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Live Attenuated Vaccines Company, Product Type & Application
  7. 3.7 Global Live Attenuated Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Vaccines Tier 1, Tier 2, and Tier 3
4 Live Attenuated Vaccines Regional Status and Outlook
  1. 4.1 Global Live Attenuated Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Live Attenuated Vaccines Historic Market Size by Region
  3. 4.2.1 Global Live Attenuated Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Live Attenuated Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Live Attenuated Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Live Attenuated Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Live Attenuated Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Live Attenuated Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Live Attenuated Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Live Attenuated Vaccines by Application
  1. 5.1 Live Attenuated Vaccines Market by Application
  2. 5.1.1 Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Live Attenuated Vaccines Market Size by Application
  7. 5.2.1 Global Live Attenuated Vaccines Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Live Attenuated Vaccines Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Live Attenuated Vaccines Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Live Attenuated Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Live Attenuated Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Live Attenuated Vaccines Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Live Attenuated Vaccines Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Live Attenuated Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Astellas Pharma
  2. 6.1.1 Astellas Pharma Company Information
  3. 6.1.2 Astellas Pharma Business Overview
  4. 6.1.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
  6. 6.1.5 Astellas Pharma Recent Developments
  7. 6.2 CSL
  8. 6.2.1 CSL Company Information
  9. 6.2.2 CSL Business Overview
  10. 6.2.3 CSL Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CSL Live Attenuated Vaccines Product Portfolio
  12. 6.2.5 CSL Recent Developments
  13. 6.3 Serum Institute Of India
  14. 6.3.1 Serum Institute Of India Company Information
  15. 6.3.2 Serum Institute Of India Business Overview
  16. 6.3.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
  18. 6.3.5 Serum Institute Of India Recent Developments
  19. 6.4 GlaxoSmithKline
  20. 6.4.1 GlaxoSmithKline Company Information
  21. 6.4.2 GlaxoSmithKline Business Overview
  22. 6.4.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
  24. 6.4.5 GlaxoSmithKline Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Live Attenuated Vaccines Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Merck
  32. 6.6.1 Merck Company Information
  33. 6.6.2 Merck Business Overview
  34. 6.6.3 Merck Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Merck Live Attenuated Vaccines Product Portfolio
  36. 6.6.5 Merck Recent Developments
  37. 6.7 Johnson & Johnson
  38. 6.7.1 Johnson & Johnson Company Information
  39. 6.7.2 Johnson & Johnson Business Overview
  40. 6.7.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
  42. 6.7.5 Johnson & Johnson Recent Developments
  43. 6.8 Sanofi
  44. 6.8.1 Sanofi Company Information
  45. 6.8.2 Sanofi Business Overview
  46. 6.8.3 Sanofi Live Attenuated Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sanofi Live Attenuated Vaccines Product Portfolio
  48. 6.8.5 Sanofi Recent Developments
7 North America by Country
  1. 7.1 North America Live Attenuated Vaccines Sales by Country
  2. 7.1.1 North America Live Attenuated Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Live Attenuated Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Live Attenuated Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Live Attenuated Vaccines Market Size by Country
  6. 7.2.1 North America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Live Attenuated Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Live Attenuated Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Live Attenuated Vaccines Sales by Country
  2. 8.1.1 Europe Live Attenuated Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Live Attenuated Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Live Attenuated Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Live Attenuated Vaccines Market Size by Country
  6. 8.2.1 Europe Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Live Attenuated Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Live Attenuated Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Live Attenuated Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Live Attenuated Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Live Attenuated Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Live Attenuated Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Live Attenuated Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Live Attenuated Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Live Attenuated Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Live Attenuated Vaccines Sales by Country
  2. 10.1.1 South America Live Attenuated Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Live Attenuated Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Live Attenuated Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Live Attenuated Vaccines Market Size by Country
  6. 10.2.1 South America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Live Attenuated Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Live Attenuated Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Live Attenuated Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Live Attenuated Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Live Attenuated Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Live Attenuated Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Live Attenuated Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Live Attenuated Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Live Attenuated Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Live Attenuated Vaccines Value Chain Analysis
  2. 12.1.1 Live Attenuated Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Live Attenuated Vaccines Production Mode & Process
  7. 12.2 Live Attenuated Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Live Attenuated Vaccines Distributors
  10. 12.2.3 Live Attenuated Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst